Completed × Leukemia, Basophilic, Acute × Clear all
NCT00003396 2019-10-17

Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer

University of Maryland, Baltimore

Phase 2 Completed
42 enrolled
NCT00003398 2019-10-17

Bone Marrow Transplantation in Treating Patients With Hematologic Cancer

University of Maryland, Baltimore

Phase 4 Completed
45 enrolled
NCT00005092 2018-10-26

Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer

M.D. Anderson Cancer Center

Phase 1 Completed
7 enrolled
NCT00295841 2018-08-10

Cytarabine and Clofarabine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia

Wake Forest University Health Sciences

Phase 1 Completed
53 enrolled
NCT01656031 2017-06-20

A Phase II Open-Label Study of High-Dose Cytarabine and Clofarabine in Adult Patients With Refractory or Relapsed Acute Myelogenous Leukemia or Refractory or Relapsed Acute Lymphoblastic Leukemia

Wake Forest University Health Sciences

Phase 2 Completed
39 enrolled 7 charts
NCT00383474 2015-04-15

Tipifarnib and Bortezomib in Treating Patients With Acute Leukemia or Chronic Myelogenous Leukemia in Blast Phase

National Cancer Institute (NCI)

Phase 1 Completed
35 enrolled
NCT00096122 2014-05-26

Idarubicin, Cytarabine, and Tipifarnib in Treating Patients With Newly Diagnosed Myelodysplastic Syndromes or Acute Myeloid Leukemia

National Cancer Institute (NCI)

Phase 1/2 Completed
95 enrolled 5 charts
NCT00098423 2013-09-30

Tanespimycin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Chronic Myelomonocytic Leukemia, or Myelodysplastic Syndromes

National Cancer Institute (NCI)

Phase 1 Completed
42 enrolled
NCT00454480 2013-08-26

Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes

National Cancer Institute (NCI)

Phase 2/3 Completed
2,000 enrolled
NCT00003395 2013-06-25

Arsenic Trioxide in Treating Patients With Advanced Hematologic Cancer

Memorial Sloan Kettering Cancer Center

Phase 1 Completed
NCT00357305 2013-05-03

Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or Myelodysplastic Syndromes or Myeloproliferative Disorders

National Cancer Institute (NCI)

Phase 1 Completed
25 enrolled
NCT00114257 2013-02-11

Decitabine and FR901228 in Treating Patients With Relapsed or Refractory Leukemia, Myelodysplastic Syndromes, or Myeloproliferative Disorders

National Cancer Institute (NCI)

Phase 1 Completed
36 enrolled
NCT00095797 2013-02-08

XK469R in Treating Patients With Refractory Hematologic Cancer

National Cancer Institute (NCI)

Phase 1 Completed
60 enrolled
NCT00131989 2013-01-09

Sorafenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia

National Cancer Institute (NCI)

Phase 1 Completed
48 enrolled
NCT00293410 2010-05-06

Clofarabine and Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Leukemia, Chronic Myelogenous Leukemia, or Myeloproliferative Disorders

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 1 Completed
70 enrolled